Pharmaceuticals
Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform,...
2025-05-06 10:01
2775
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2025-05-06 08:00
3864
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagoni...
2025-05-06 07:00
2580
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...
2025-05-04 14:48
3908
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
* Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in July * With a fully modular design, CURECATM introduces a bold vision for automating pre-treatment across diverse PCR specimen types * Developed for future integration into unattended work...
2025-05-02 21:00
7441
CPHI South East Asia 2025: Your gateway to ASEAN's expanding pharmaceutical landscape
KUALA LUMPUR, Malaysia, May 2, 2025 /PRNewswire/ -- As Southeast Asia's pharmaceutical industry rapidly evolves—driven by regulatory harmonization, innovation, and growing healthcare demand—CPHI South East Asia 2025 provides a vital platform to connect with regional stakeholders, showcase breakth...
2025-05-02 19:25
6926
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemother...
2025-05-01 09:49
3413
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd.
2025-05-01 08:00
3266
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital ofSichuan University, recently announced the successful completion of first-in-human ("FIH") feasibility study of its innovative, proprie...
2025-04-30 21:00
2524
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association for Cancer Research (AACR) annual meeting, held from Ap...
2025-04-30 20:00
2775
Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach
PRAGUE and BUDAPEST, Hungary, April 30, 2025 /PRNewswire/ -- Modern medical
treatment options for endometriosis were among the main topics at the SEUD
Congress
2025-04-30 19:00
2541
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical Phase 1/2 results) and the ovarian cancer treatment candidate 'JIN-001' (preclinic...
2025-04-30 13:03
2734
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...
2025-04-30 10:35
3579
Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2025-04-30 08:00
3637
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...
2025-04-30 07:45
3124
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:39
3909
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:38
3330
Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools
The combination of metagenomics and metabolomics data, integrated within an intuitive bioinformatics platform, enables deeper microbiome insights than possible with either approach individually MORRISVILLE, N.C., April 29, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing met...
2025-04-29 21:00
2068
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effectiveness for corporate governance * Empowering employees and delivering positive impact to communities * Accelerating actions for tackling climate change and promoting environmental stewardship ...
2025-04-29 18:47
3009
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025 EU approval is b...
2025-04-29 14:00
2778
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
14603
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
14347